Higher Visceral Adipose Tissue May Need Higher Infliximab Levels for IBD Remission
By Lori Solomon HealthDay Reporter
WEDNESDAY, Nov. 15, 2023 -- Patients with inflammatory bowel disease (IBD) and high visceral adipose tissue (VAT) may have more difficulty achieving higher infliximab levels necessary to achieve remission, according to a study published in the November issue of the American Journal of Gastroenterology.
Andres J. Yarur, M.D., from Cedars Sinai Medical Center in Los Angeles, and colleagues assessed whether VAT burden may be associated with infliximab cutoffs associated with efficacy in patients with IBD. The analysis included 142 patients with IBD receiving maintenance infliximab therapy.
The researchers found that the optimal trough levels of infliximab cutoffs associated with steroid-free deep remission and endoscopic remission were 3.9 μg/mL (Youden Index [J], 0.52) for patients in the lowest two VAT quartiles (<1.2 percent). For patients in the highest two VAT quartiles, the optimal infliximab-level cutoff associated with steroid-free deep remission was 15.3 mcg/mL (J, 0.63). Only VAT percentage and infliximab level remained independently associated with steroid-free deep remission (odds ratio per percentage of VAT, 0.3; odds ratio per μg/mL, 1.11).
"Patients with IBD and a higher VAT burden may require a higher infliximab exposure to achieve clinical and endoscopic remissions," the authors write. "Although the exact mechanism is still unclear, clinicians should consider aiming for higher drug concentrations before abandoning infliximab in a nonresponder with a higher VAT burden."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...
Study IDs Risk Factors for Extraintestinal Manifestations of IBD
WEDNESDAY, April 17, 2024 -- Certain demographic, clinical, and genetic factors heighten the risk for extraintestinal manifestations (EIMs) with inflammatory bowel disease (IBD)...
Higher Vitamin D Levels Cut Bowel Resection Risk With IBD
WEDNESDAY, April 3, 2024 (HealthDay News) -- An increased serum level of 25-hydroxyvitamin D (25[OH]D) is independently associated with a lower risk for bowel resection with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.